Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
8/21/2025
Novo Nordisk Meets NHC Minister to Strengthen Collaboration
8/21/2025
NMPA Lifts Import Suspension on Vasudha's Loratadine API
8/21/2025
CStone Gains Major Backing as GIC Acquires 5.49% Stake
8/21/2025
Bio-Thera Solutions Taps STADA to Bring BAT1806 to Global Markets
8/21/2025
Zelgen Secures FDA IND Approval for Novel Trispecific Cancer Therapy
8/21/2025
Novartis' Vanrafia (atrasentan) Gains Regulatory Nod in China as Secon...
8/21/2025
Nicox Targets U.S. and China Filings After Second Phase III Win for NC...
8/21/2025
Henlius Biotech Expands Oncology Portfolio with Strategic Licensing Ag...
8/21/2025
China Proposes Conflict-of-Interest Declarations for Drug Clinical Tri...
8/21/2025
China Drafts Guidance on Single-Arm Trials to Support Oncology Drug Ap...
8/20/2025
China Drives Asia-Pacific Health Care Transformation Amid Rising Costs...
8/20/2025
Vivatides Secures Major Seed Funding to Propel Breakthrough in Oligonu...
8/20/2025
Pfizer Advances Pneumococcal Vaccine Development in China with Phase 1...
8/19/2025
Eisai Launches First Orexin Receptor Antagonist for Insomnia in China
8/19/2025
Onconic's GERD Drug Jaqbo Advances in China Following Phase 3 Success
8/19/2025
CSPC Pharma Advances in Biosimilars with Dupilumab Injection Approval
8/19/2025
China Unveils Nine Key Healthcare Insurance Priorities for 2025
8/19/2025
Innovent Presents Phase 2 Study of Tarlatamab in Third-Line ES-SCLC at...
8/19/2025
Aeonvital Biomedical Advances Personalized Cancer Therapies with New F...
8/19/2025
RemeGen and Santen Enter into Licensing Deal for Ophthalmic Drug RC28-...
8/19/2025
BioNTech's BNT327 Shows Strong Phase II Results as China-Originated Dr...
8/19/2025
CANbridge Announces Strategic Partnership and Investment from Baheal
8/18/2025
Pleryon Completes First Closing of Series A Financing
8/18/2025
Yixuan Secures Angel Financing to Advance Novel Nucleic Acid Drug Deve...
8/18/2025
Aoda Raises CNY30M Series A to Advance Dual-Receptor Agonist Program
8/18/2025
Latticon Completes Series A Financing to Advance Trial of LAT010 Immun...
8/18/2025
Tarlatamab Shows Promising Results in Chinese Phase 2 Trial for Heavil...
8/15/2025
NHSA Issues Interim Measures for Disease-Based Medical Insurance Payme...
8/15/2025
Guangzhou Innogen Pharma Debuts on HKSE Amid Expanding Metabolic Pipel...
8/14/2025
CDE Seeks Public Input on Draft Guidelines for Bayesian Methods in Cli...
Page:
5
/
58
Total number of articles:
1735
:
[First]
[<<]
[3]
[4]
[5]
[6]
[7]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit